Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial

TAGS

Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase 2b/3 clinical trial in neovascular (wet) age-related macular degeneration (wet AMD).

The primary endpoint of the trial was achieving non-inferior visual acuity gains with the treatment of KSI-301, which is an anti–vascular endothelial growth factor therapy (anti-VEGF therapy) in comparison to aflibercept administered every eight weeks.

The randomized, double-masked, active comparator-controlled clinical trial assessed the efficacy, durability and safety of the antibody biopolymer conjugate in 559 participants, of whom nearly 80% were enrolled in the US, said the California-based retinal medicines development company.

See also  Panic at mall in Michigan: Violent late night shooting shakes Lansing

Kodiak Sciences had split the wet AMD clinical trial into two treatment arms, with one of them receiving KSI-301 5mg on a flexible long-interval regimen and the other subjected to aflibercept 2mg on a fixed short-interval regimen.

As per the results, KSI-301 showed strong durability and was safe and well tolerated, but could not register non-inferior visual acuity gains for patients dosed on extended regimens.

See also  Cargill, Continental Grain close $4.5bn acquisition of Sanderson Farms

A pre-specified secondary analysis at year 1 assessing durability showed 59% of patients in the KSI-301 arm achieved five-month dosing with visual acuity gains and anatomic improvements comparable to the overall aflibercept group.

Victor Perlroth — Kodiak Sciences CEO said: “Allowing treatment with KSI-301 no more often than every 12 weeks after the loading phase for every patient turned out to be insufficient.

See also  Gathered Foods opens production plant in Ohio for Good Catch products

“Nonetheless, we believe the results demonstrate a clear anti-VEGF effect, strong durability and a reassuring safety profile. We think that these data continue to support the potential of our ABC Platform to significantly extend treatment intervals in retinal disorders in a safe and convenient manner.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This